LAG3 and prostate carcinoma: Camisaschi et al. revealed that inside the suppressor CD4+CD25highFOXP3+ T cell population, LAG-3 expression identified a subset of Tregs cells that displayed a terminal-effector phenotype and was expanded in peripheral blood and from patients with different types of cancer, among them prostate cancer [49].